BNGO - Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting | Benzinga
- A sponsored session will feature Dr. Brynn Levy from Columbia University Medical Center, Dr. Roger Stevenson, founder of Greenwood Genetic Center, and Dr. Alex Hastie from Bionano presenting on the utility of optical genome mapping (OGM) across constitutional genetics research applications
- An industry co-lab session led by Dr. Sam Dougaparsad from Bionano will provide attendees with an overview of Bionano's end-to-end OGM workflow, including details of the latest product developments and innovations to enhance, streamline and enable scalability
- Three additional scientific presentations will highlight the use of OGM in neurodevelopmental and prenatal research applications
- Twelve scientific posters will illustrate the application of OGM in research areas including hematological malignancies, genetic disorders, and cell manufacturing and bioprocessing quality control
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the American Society of Human Genetics (ASHG) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) for cell bioprocessing quality control and constitutional genetic disorder research, including scientific platform and poster presentations from Bionano and researchers from across the genomics landscape.
ASHG's annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics and genetics research. The ASHG conference will be held November 1-5, 2023, in Washington, D.C.
As part of a sponsored session, Dr. Brynn Levy of Columbia University Medical Center, Dr. Roger Stevenson, founder of Greenwood Genetic Center, and Dr. Alex Hastie, Bionano's vice president of clinical and scientific affairs, will share their latest research covering the utility of OGM in constitutional genetic research. Dr. Levy will present findings from the largest multisite study to date comparing OGM to classical cytogenetic methods for postnatal constitutional disorder research. Dr. Stevenson will discuss his research using OGM for the analysis of neural tube defects. The session will take place on Thursday, November 2 at 12:30 PM ET in Room 143C.
As part of a hosted CoLab session, Bionano's senior technical specialist, Dr. Sam Dougaparsad, will host a discussion titled "Optical Genome Mapping as a Comprehensive Workflow for Revealing Structural Variants." In the session, Dr. Dougaparsad will discuss how the OGM workflow offers researchers a transformative technique for high-resolution, genome-wide, comprehensive analysis of structural variation across research in cancer and genetic disease. The presentation will take place Friday, November 3, from 1:05-1:35 PM ET in the CoLab Theatre 1 room.
Three separate scientific presentations highlighting the utility of OGM will be given. Dr. Christopher Grochowksi of Baylor College Medicine will present on the use of OGM in neurodevelopmental disorder research. Dr. Jesse Bengtsson of Pacific Northwest Research Institute will present on the use of OGM to analyze complex genomic rearrangements in MECP2 duplication syndrome. Dr. Brynn Levy will present findings from the first large-scale study to use OGM instead of conventional cytogenetic methods for prenatal genetic analysis.
In addition, 12 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.
Scientific presentations and poster sessions from Bionano and collaborators include:
Poster Number |
Title |
Author |
Presented |
PB3258 |
Optical genome mapping identified a KMT2C exonic deletion in a Kleefstra syndrome subject resulting from maternal mosaicism |
Brassell B. |
November 2, 2023 3:00-5:00 PM ET |
PB3162 |
Automated ultra-high molecular weight DNA isolation from various sources enables high-throughput optical genome mapping |
Hoischen A. |
November 2, 2023 3:00-5:00 PM ET |
PB3291 |
Update to the CLIA diagnostic procedure using optical genome mapping for the diagnosis of facioscapulohumeral dystrophy |
Jang J. |
November 2, 2023 3:00-5:00 PM ET |
PB4978 |
B-allele frequency-based approach to detecting absence of heterozygosity enables detection of low-level mosaic events using optical genome mapping |
Raksi A. |
November 2, 2023 3:00-5:00 PM ET |